Kinnate Raises $35 Million to Bring Assets to China

Kinnate, a San Diego biopharma. closed a $35 million Series A financing to form a China joint venture that will develop Kinnate's oncology drugs in Greater China. The round was led by OrbiMed Asia Partners, with participation from OrbiMed Private Investments and Foresite Capital. Wenn Sun, PhD, a veteran biopharma executive, was appointed Executive Chair of the JV. Initially, the unnamed JV will focus on KIN-2787,  a Rapidly Accelerated Fibrosarcoma (RAF) inhibitor aimed at lung cancer, melanoma, and other solid tumors. More details.... Stock Symbol: (NSDQ: KNTE) Share this with colleagues: // //